VeraMorph
VeraMorph: Innovating polymer-based oral dosage technology in pharmaceuticals since 2017.
Founded
2017VeraMorph: Innovating polymer-based oral dosage technology in pharmaceuticals since 2017.
Founded in 2017 and headquartered in Mansfield, Massachusetts, VeraMorph is a pharmaceutical company dedicated to innovating polymer-based oral dosage technology. The company's core mission is to maximize the therapeutic potential of poorly soluble small molecules, thereby improving and accelerating the clinical translation of these compounds. VeraMorph offers a proprietary oral drug delivery platform aimed at enhancing the bioavailability and efficacy of lead compounds, ultimately building a specialty drug product portfolio with clinically differentiated solutions.
VeraMorph's notable affiliations include partnerships with leading pharmaceutical companies seeking to leverage its advanced drug delivery technology. The company has garnered attention from key investors in the biotech and pharmaceutical sectors, contributing to its rapid growth and development. VeraMorph's key achievements include successful collaborations that have led to significant advancements in drug formulation and delivery. Overall, VeraMorph's impact lies in its ability to transform poorly soluble compounds into viable therapeutic options, addressing critical needs in the pharmaceutical industry.
Companies similar to VeraMorph include Concours Pharmaceuticals, Morphic Therapeutic, Syntis Bio and Nanocopoeia.
VeraMorph was founded in 2017.
VeraMorph's headquarters is located in Mansfield, MA, US.
VeraMorph's most recent funding round was for $225k (USD) in August 2020.
As of Aug 13, 2020, VeraMorph has disclosed funding of $225k (USD). Undisclosed round amounts are excluded.
VeraMorph has 2 employees as of Feb 5, 2024.
Nanocopoeia
nanocopoeia.com
